In a report released today, Colin Bristow from UBS maintained a Buy rating on Nanobiotix (NBTX – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $7.65.
Bristow covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Regeneron. According to TipRanks, Bristow has an average return of 4.1% and a 54.44% success rate on recommended stocks.
Currently, the analyst consensus on Nanobiotix is a Moderate Buy with an average price target of $11.50.
See Insiders’ Hot Stocks on TipRanks >>
NBTX market cap is currently $366.4M and has a P/E ratio of -4.36.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nanobiotix (NBTX) Company Description:
Nanobiotix SA is a late-stage clinical company engaged in developing and selling nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company’s products include NBTXR3, a preclinical research program for cancer immunotherapies.
Read More on NBTX:
- Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
- Voting Rights and Shares Capital of the Company
- Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson
- Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
- Nanobiotix initiated with an Outperform at Leerink
